Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: A meta-analysis

• DOI: 10.21203/rs.2.16950/v3
• Publication Date: 2020-07-14T16:11:46Z
• Authors: Lin He; Yaling Wang; Qian Wu; Yuhua Song; Xuezhen Ma; Biyuan Zhang; Haiji Wang; Yong Huang
• Keywords: Tumor-infiltrating lymphocytes

Abstract Background: To investigate the impact of elevation tumor-infiltrating lymphocytes (TILs) in different molecular subtypes primary breast cancer, i.e. each 10% increment TILs and high-level (TILs≥50%) tumor, on overall survival (OS) pathological complete response (pCR) to compare presentation across these subtypes. Methods: Citation retrieval was performed PubMed, Cochrane Library, Embase Web Science databases. All statistical calculations were by software StataSE version 12.0. Results: Twenty-two eligible clinical trials including 15676 unique patients included for meta-analysis. Each significantly improved OS human epidermal growth factor receptor 2 (HER2)-overexpression (pooled Hazard ratio (HR), 0.92; 95% CI, 0.89-0.95) triple-negative (TN) HR, 0.90; 0.89-0.92) tumors but not luminal tumor subtype 1.06; 0.99-1.13). It also associated with an increased pCR rate cancers Odds (OR), 1.27; 1.19-13.5). High-level related a higher OR, 2.73; 2.40-3.01) than low-level TILs. The HER2-amplified 3.14; 1.95-5.06) TN 4.09; 2.71-6.19) phenotypes expressed more subtype, although those between former two subsets 1.30; 95%CI, 0.83-2.04). Conclusions: predicts favorable prognostic outcomes, particularly HER2-overexpression